Supplemental Figure 1









Supplemental Figure 1. PAM50 classification of metastatic prostate cancer associates with phenotypes and genotypes. (A) PAM50 classification using the SU2C RNAseq probe-capture dataset partitions mCRPC tumors into LumA, LumB and Basal subtypes. Fold difference scale reflects mean-centered log2 FPKM values from RNAseq. Molecular signature scores and phenotypes shown at the top of plot and colored according to legends at the right side.**(B,D)** mCRPCs with neuroendocrine (NE) characteristics are predominantly classified into the PAM50 Basal subtype whereas the common AR active/NE negative mCRPCs are subclassified into LumA, LumB and Basal subtypes. **(C,E)** PAM50 subtypes are not associated with common genomic alterations observed in mCRPC except for *RB1* loss which is enriched in the PAM50 Basal subtype compared to LumA and LumB, *TMPRSS2-ERG* fusion event enrichment in LumB compared to Basal, and Chr8q-gain in LumB compared to LumA tumors. T2-ERG, *TMPRSS2-ERG* fusion; RB1-BAL, bi-allelic loss of *RB1*; TP53-BAL, bi-allelic loss of *TP53*; CSig3, COSMIC mutational 'Signature 3'; HRG-BAL, bi-allelic loss of core homology directed DNA repair genes; CDK12-BAL, bi-allelic loss of *CDK12*.